Skip to content

What is Vaccinium parvifolium? — PlantSage

0Vaccinium parvifolium·What is5 answers
0Section · 00

What is Vaccinium parvifolium

— Short, snippet-friendly answers to the most-asked questions about Vaccinium parvifolium (Vaccinium parvifolium). For the full profile with citations, open the main page.

What is Vaccinium parvifolium?

Vaccinium parvifolium, known as the dwarf bilberry or small-leaved blueberry, is a perennial shrub native to coastal regions from Alaska to California and into parts of British Columbia and Washington. Vaccinium parvifolium (Latin: Vaccinium parvifolium) is a medicinal plant catalogued in PlantSage.

What is Vaccinium parvifolium used for?

Vaccinium parvifolium is most often used to support digestion and immune support. Each claim is rated by evidence strength - see the full profile for citations.

Is Vaccinium parvifolium safe?

Vaccinium parvifolium is generally considered safe when used at traditional doses. Always consult a clinician before using any herbal preparation — especially during pregnancy, breastfeeding, while on medication, or for children.

Where does Vaccinium parvifolium grow?

Vaccinium parvifolium is a member native to ASK, BRC, CAL, ORE, and WAS. Vaccinium parvifolium thrives in partial sun to full sun and prefers moist, well-draining soils that are light (sandy) or medium textured.

Can I grow Vaccinium parvifolium at home?

Vaccinium parvifolium grows best in USDA zone 5-9, full sun, partial sun/shade light, moist water, and perennial life cycle. Detailed sowing, propagation, and care notes are on the full profile.

Full profile Safety by audience →Preparation forms →Edible plants index →Browse catalogue →
❦❦❦❦
Endpaper · archive updates

Primește digest-ul săptămânal

Un email curat pe săptămână — profile noi de plante, note sezoniere de cultivare, adăugiri în arhiva de remedii. Gratuit, fără tracking, dezabonare oricând.

Newsletter returning soon.
We are rebuilding the update list around a lightweight editorial workflow. New dispatches will resume after the next content review cycle.